L'hospitalet De Llobregat

• A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis Ended
  2023-510249-79-00 4 2024-09-10 Progressive pulmonary fibrosis (PPF)
• Phase Ib Clinical Trial to Evaluate the Safety Profile of the Combination Tilray FS Oral Solution T10:C10 with Temozolomide and Radiotherapy … Ended
  2024-515546-16-00 3 2024-08-27 Glioblastoma
• A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni … Ended
  2023-505755-40-00 4 2024-08-16 Chronic kidney disease
• A Phase 3, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adu … Ended
  2023-507268-37-00 5 2024-07-29 Hereditary Angioedema
• A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr … Ended
  2023-506185-31-00 10 2024-07-18 Idiopathic pulmonary fibrosis (IPF)
• A Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer Ended
  2022-502982-49-00 4 2024-07-15 Metastatic Castration-Resistant Prostate Cancer
• Phase 2b study to investigate the safety and efficacy of TIN816 in SA-AKI Ended
  2023-505903-22-00 4 2024-07-02 Sepsis associated acute kidney injury
• A safety study of PF-08046045/SGN-35T in adults with advanced cancers Ended
  2022-502390-41-00 1 2024-06-20 Enteropathy-Associated T-Cell Lymphoma
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer
• A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr … Ended
  2023-508663-70-00 4 2024-06-18 Bronchiectasis
• A study on the immune response and safety of a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccin … Ended
  2023-510196-59-00 5 2024-06-15 Respiratory Syncytial Virus Infections
• EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer Ended
  2023-509336-25-00 9 2024-06-12 Metastatic castration-resistant prostate cancer
• A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Ended
  2023-507324-23-00 4 2024-05-22 recurrent or persistent uterine serous carcinoma
• A study to learn how safe starting vericiguat at a dose of 5 milligrams is in participants with chronic heart failure with reduced ejection … Ended
  2023-507682-25-00 4 2024-05-13 Chronic heart failure with reduced ejection fraction
• MYK-224 in Heart Failure with Preserved Ejection Fraction (HFpEF) Ended
  2023-505919-21-00 4 2024-04-25 Heart failure with preserved ejection fraction (HFpEF)
• A Multicenter, Randomized, Double-Blind, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin-X … Ended
  2022-501952-27-00 5 2024-04-19 Hospital-acquired bacterial pneumonia (HABP), including ventilated HAB
• A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended
  2023-505857-42-00 4 2024-04-19 Chronic Kidney Disease, Type 2 diabetes
• A study to learn how safe and tolerable odronextamab and cemiplimab are in adult patients with B-cell malignancies Ended
  2023-508209-25-00 1 2024-04-19 B-Cell Non-Hodgkin’s Lymphoma (B-NHL)
• A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Pos … Ended
  2023-506038-65-00 4 2024-04-15 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CA
• Comparison of three short rifamycin-based regimens to treat latent tuberculosis in patients with end-stage kidney disease. Ended
  2023-506432-32-00 6 2024-04-11 Latent tuberculosis infection in patients with end-stage kidney diseas
• A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi … Ended
  2022-501421-20-00 5 2024-04-09 Gout with hyperuricemia
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended
  2023-506707-25-00 5 2024-04-09 Choroidal neovascularization secondary to pathologic myopia
• Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7. Ended
  2022-501969-42-00 5 2024-03-28 Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criter
• GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: a single-arm interventional clinical trial. Study 2 … Ended
  2023-506436-33-00 5 2024-03-22 Metabolic syndrome in patients on the waiting list for kidney transpla

Showing 817–840 of 1,017 trials